Know Cancer

forgot password

A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects With Small Cell Lung Cancer or Other Non-Hematological Malignancies

Phase 1/Phase 2
18 Years
Not Enrolling
Small Cell Lung Cancer, Small Cell Lung Carcinoma

Thank you

Trial Information

A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects With Small Cell Lung Cancer or Other Non-Hematological Malignancies

Inclusion Criteria:

- The subject must be >=18 years of age.(Phase 1 & 2a)

- Histologically and/or cytologically documented diagnosis of small cell lung cancer
(North America & UK) or other non-hematological malignancy (North America
only).(Phase 1 only)

- Histologically and/or cytologically documented diagnosis of SCLC.(Phase 2a)

- At least one prior chemotherapy treatment regimen(s) and their disease is refractory
or experienced progressive disease following the treatment.(Phase 1)

- Extensive-stage SCLC & is chemotherapy naïve(US only) has experienced progressive
disease following at least one chemotherapy regimen or their disease is
refractory.(Phase 2a)

- Brain metastases with clinically controlled neurologic symptoms, defined as surgical
excision and/or radiation therapy followed by 21 days of stable neurologic function &
no evidence of CNS disease progression as determined by CT or MRI within 21 days
prior to the first dose of study drug.

- ECOG performance score <= 2(Ph 1) <=1(Phase 2a)

- Must be receiving a stable dose of Selective Serotonin Reuptake Inhibitor (SSRI)
anti-depressants 21 days prior to 1st dose of study drug.

- Adequate bone marrow, renal & hepatic function per local lab reference range at
Screening as follows:

- Bone marrow: Absolute Neutrophil count (ANC)>=1000/µL

- Platelets>= 100,000/mm3

- Hemoglobin>=9.0g/dL

- Renal function: Serum creatinine<= 2.0mg/dL or calculated creatinine

- Hepatic function&enzymes: AST and ALT<=3.0 x the upper normal limit(ULN) of
institution's normal range

- Bilirubin<=1.5xULN. If Gilbert's Syndrome may have Bilirubin> 1.5 x ULN

- Coagulation: aPTT and PT<=1.2 x the upper limit of normal

- Should have archived diagnostic tissue available for assessment of Bcl-2 family
protein expression.(Phase 2a)

- All female subjects not surgically sterile or postmenopausal(for at least 1 year)and
non-vasectomized male subject must practice at least one method of birth control.

Exclusion Criteria:

- Underlying or predisposing condition of bleeding or currently exhibits signs of

- Recent history of non-chemotherapy induced thrombocytopenia associated bleeding
within 1 year prior to first dose of study drug.

- Active peptic ulcer disease or other potentially hemorrhagic esophagitis/gastritis.

- The subject has active immune thrombocytopenic purpura (ITP),active autoimmune
hemolytic anemia (AIHA), or a history of being refractory to platelet transfusions
(within 1 year prior to the first dose of study drug).

- Currently receiving or requires anticoagulation therapy or any drug or herbal
supplements that affect platelet function, with exception of low-dose anticoagulation
medications that are used to maintain the patency of a central intravenous catheter.

- Received any anti-cancer therapy including chemotherapy, immunotherapy, radiotherapy,
hormonal (with the exception of hormones for hypothyroidism or estrogen replacement
therapy (ERT), anti estrogen analogs, agonists required to suppress serum
testosterone levels), or any investigational therapy within 14 days prior to the
first dose of study drug, or has not recovered to less than a grade 2 adverse
effect(s) of the previous therapy.

- Received a biologic (G-CSF, GM-CSF or erythropoietin) within 28 days prior to the
first dose of study drug.

- Steroid therapy for anti-neoplastic intent within seven days prior to the first dose
of study drug.

- Has consumed grapefruit or grapefruit products within 3 days prior to the first dose
of study drug.

- Significant history of cardiovascular disease, renal, neurologic, psychiatric,
endocrinologic, metabolic, immunologic, or hepatic disease that in the opinion of the
investigator would adversely affect his/her participating in this study.

- Positive for HIV

- A history of other active malignancies within the past 3 years prior to screening,
with the exception of:

- Adequately treated in situ carcinoma of the cervix uteri

- Basal or squamous cell carcinoma of the skin

- Previous malignancy confined and surgically resected with curative intent

- Evidence of other clinically significant uncontrolled condition(s) including, but not
limited to:

- Active systemic fungal infection

- Diagnosis of fever and neutropenia within 1 week prior to study drug

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Safety assessment

Outcome Time Frame:

Repeating sequence of 14 days on therapy and 7 days off or continuous dosing

Safety Issue:



United States: Food and Drug Administration

Study ID:




Start Date:

April 2007

Completion Date:

December 2010

Related Keywords:

  • Small Cell Lung Cancer
  • Small Cell Lung Carcinoma
  • SCLC
  • Carcinoma
  • Lung Neoplasms
  • Small Cell Lung Carcinoma



Site Reference ID/Investigator# 13605 Peoria, Arizona  85381
Site Reference ID/Investigator# 5261 Phoenix, Arizona  85013
Site Reference ID/Investigator# 11942 Los Angeles, California  90095-7187
Site Reference ID/Investigator# 4718 Sacramento, California  95817
Site Reference ID/Investigator# 3755 Aurora, Colorado  80045-0510
Site Reference ID/Investigator# 8324 Atlanta, Georgia  30322
Site Reference ID/Investigator# 2623 Chicago, Illinois  60612
Site Reference ID/Investigator# 2625 Baltimore, Maryland  21231-1000
Site Reference ID/Investigator# 12343 Bethesda, Maryland  20892
Site Reference ID/Investigator# 2626 Boston, Massachusetts  02215
Site Reference ID/Investigator# 11941 Boston, Massachusetts  02215
Site Reference ID/Investigator# 4934 Charlotte, North Carolina  28204
Site Reference ID/Investigator# 2624 Nashville, Tennessee  37203
Site Reference ID/Investigator# 6650 Tacoma, Washington  98405